NASDAQ:ATRC AtriCure (ATRC) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free ATRC Stock Alerts $20.89 -1.33 (-5.99%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$20.78▼$23.0350-Day Range$20.89▼$37.7852-Week Range$20.19▼$59.61Volume961,862 shsAverage Volume881,737 shsMarket Capitalization$994.16 millionP/E RatioN/ADividend YieldN/APrice Target$49.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get AtriCure alerts: Email Address AtriCure MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside138.3% Upside$49.78 Price TargetShort InterestBearish6.72% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 30 Articles This WeekInsider TradingSelling Shares$504,932 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.75) to ($0.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.08 out of 5 starsMedical Sector380th out of 904 stocksSurgical & Medical Instruments Industry47th out of 96 stocks 4.5 Analyst's Opinion Consensus RatingAtriCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtriCure has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.72% of the outstanding shares of AtriCure have been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in AtriCure has recently decreased by 1.54%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATRC. Previous Next 1.7 News and Social Media Coverage News SentimentAtriCure has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for AtriCure this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for ATRC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added AtriCure to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $504,932.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of AtriCure is held by insiders.Percentage Held by Institutions99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AtriCure are expected to grow in the coming year, from ($0.75) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is -26.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is -26.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About AtriCure Stock (NASDAQ:ATRC)AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.Read More ATRC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATRC Stock News HeadlinesMay 4, 2024 | insidertrades.comAtriCure, Inc. (NASDAQ:ATRC) Insider Sells $36,135.00 in StockMay 5, 2024 | americanbankingnews.comJustin J. Noznesky Sells 1,500 Shares of AtriCure, Inc. (NASDAQ:ATRC) StockMay 5, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.May 4, 2024 | finance.yahoo.comAtriCure, Inc. (NASDAQ:ATRC) Just Reported, And Analysts Assigned A US$47.33 Price TargetMay 4, 2024 | americanbankingnews.comAtriCure (NASDAQ:ATRC) Stock Price Down 5.5% After Insider SellingMay 4, 2024 | americanbankingnews.comAtriCure, Inc. (NASDAQ:ATRC) Receives Average Rating of "Buy" from BrokeragesMay 3, 2024 | markets.businessinsider.comAtricure’s Strong Performance and Growth Potential Affirm Buy RatingMay 3, 2024 | finance.yahoo.comAtriCure First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 5, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.May 3, 2024 | finance.yahoo.comThe past three years for AtriCure (NASDAQ:ATRC) investors has not been profitableMay 3, 2024 | americanbankingnews.comAtriCure (NASDAQ:ATRC) Sets New 1-Year Low on Disappointing EarningsMay 2, 2024 | markets.businessinsider.comAtricure’s Growth and Resilience Reinforce Buy RatingMay 2, 2024 | finance.yahoo.comAtriCure, Inc. (NASDAQ:ATRC) Q1 2024 Earnings Call TranscriptMay 2, 2024 | markets.businessinsider.comAtriCure’s Strong Growth and Market Position Justify Buy RatingMay 2, 2024 | finance.yahoo.comAtriCure Inc (ATRC) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...May 1, 2024 | investorplace.comATRC Stock Earnings: AtriCure Misses EPS, Beats Revenue for Q1 2024May 1, 2024 | finance.yahoo.comAtriCure Inc (ATRC) Surpasses Revenue Estimates in Q1 2024 Despite Wider LossesMay 1, 2024 | businesswire.comAtriCure Reports First Quarter 2024 Financial ResultsApril 30, 2024 | markets.businessinsider.comAtriCure is about to announce its earnings — here's what Wall Street expectsApril 30, 2024 | businesswire.comAtriCure to Participate in the 2024 Bank of America Securities Healthcare ConferenceApril 25, 2024 | americanbankingnews.comAtriCure (NASDAQ:ATRC) Shares Gap Up to $22.71April 23, 2024 | msn.comAtriCure upgraded at Oppenheimer on valuationApril 22, 2024 | finance.yahoo.comAtriCure, Inc. (ATRC) Stock Price, News, Quote & History - Yahoo FinanceApril 20, 2024 | nasdaq.comFirst Week of June 21st Options Trading For AtriCure (ATRC)April 20, 2024 | investing.comAtriCure launches advanced cryoablation probe to expedite surgeriesApril 18, 2024 | businesswire.comAtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain ManagementApril 10, 2024 | businesswire.comAtriCure to Announce First Quarter 2024 Financial ResultsSee More Headlines Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today5/05/2024Next Earnings (Estimated)7/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ATRC CUSIP04963C20 CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees1,200Year Founded2000Price Target and Rating Average Stock Price Target$49.78 High Stock Price Target$68.00 Low Stock Price Target$32.00 Potential Upside/Downside+138.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,440,000.00 Net Margins-8.98% Pretax Margin-7.48% Return on Equity-7.82% Return on Assets-6.02% Debt Debt-to-Equity Ratio0.15 Current Ratio3.57 Quick Ratio2.66 Sales & Book Value Annual Sales$399.24 million Price / Sales2.49 Cash FlowN/A Price / Cash FlowN/A Book Value$9.84 per share Price / Book2.12Miscellaneous Outstanding Shares47,590,000Free Float46,065,000Market Cap$994.16 million OptionableOptionable Beta1.41 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Michael H. Carrel (Age 53)CEO, President & Director Comp: $2.01MMs. Angela L. Wirick CPA (Age 46)Chief Financial Officer Comp: $841.54kMr. Douglas J. Seith (Age 58)Chief Operating Officer Comp: $1.2MMr. Salvatore Privitera J.D. (Age 57)Chief Technical Officer Comp: $758.8kMr. Karl S. Dahlquist CCEP (Age 53)J.D., Chief Legal Officer Comp: $762.39kDr. Vinayak Doraiswamy Ph.D. (Age 52)Chief Scientific Officer Comp: $777.66kValerie Storch-WillhausVice President of Corporate Marketing & CommunicationsMr. Justin J. Noznesky (Age 46)Chief Marketing & Strategy Officer Comp: $644.73kMs. Deborah Yount (Age 58)Chief Human Resources Officer Comp: $498.36kMore ExecutivesKey CompetitorsCardiovascular SystemsNASDAQ:CSIIAlphatecNASDAQ:ATECOrthofix MedicalNASDAQ:OFIXSurmodicsNASDAQ:SRDXInovio PharmaceuticalsNASDAQ:INOView All CompetitorsInsiders & InstitutionsGSA Capital Partners LLPBought 14,194 shares on 5/3/2024Ownership: 0.074%Larson Financial Group LLCSold 1,363 shares on 5/3/2024Ownership: 0.036%BNP Paribas Financial MarketsSold 11,184 shares on 5/1/2024Ownership: 0.185%Justin J NozneskySold 1,500 sharesTotal: $36,135.00 ($24.09/share)Mirae Asset Global Investments Co. Ltd.Sold 1,000 shares on 5/1/2024Ownership: 0.042%View All Insider TransactionsView All Institutional Transactions ATRC Stock Analysis - Frequently Asked Questions Should I buy or sell AtriCure stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATRC shares. View ATRC analyst ratings or view top-rated stocks. What is AtriCure's stock price target for 2024? 7 brokers have issued 12-month price objectives for AtriCure's shares. Their ATRC share price targets range from $32.00 to $68.00. On average, they expect the company's stock price to reach $49.78 in the next twelve months. This suggests a possible upside of 138.3% from the stock's current price. View analysts price targets for ATRC or view top-rated stocks among Wall Street analysts. How have ATRC shares performed in 2024? AtriCure's stock was trading at $35.69 at the beginning of the year. Since then, ATRC stock has decreased by 41.5% and is now trading at $20.89. View the best growth stocks for 2024 here. Are investors shorting AtriCure? AtriCure saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,250,000 shares, an increase of 9.4% from the March 15th total of 2,970,000 shares. Based on an average daily volume of 668,700 shares, the days-to-cover ratio is currently 4.9 days. View AtriCure's Short Interest. When is AtriCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 23rd 2024. View our ATRC earnings forecast. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) posted its quarterly earnings results on Wednesday, May, 1st. The medical device company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.02. The medical device company had revenue of $108.90 million for the quarter, compared to the consensus estimate of $106.86 million. AtriCure had a negative trailing twelve-month return on equity of 7.82% and a negative net margin of 8.98%. The business's quarterly revenue was up 16.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.23) earnings per share. What ETF holds AtriCure's stock? iShares U.S. Medical Devices ETF holds 322,356 shares of ATRC stock, representing 0.14% of its portfolio. What guidance has AtriCure issued on next quarter's earnings? AtriCure updated its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share (EPS) guidance of -0.820--0.740 for the period, compared to the consensus estimate of -0.740. The company issued revenue guidance of $459.0 million-$466.0 million, compared to the consensus revenue estimate of $461.3 million. What is Michael Carrel's approval rating as AtriCure's CEO? 38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Pfizer (PFE) and Sarepta Therapeutics (SRPT). Who are AtriCure's major shareholders? AtriCure's stock is owned by a number of retail and institutional investors. Top institutional investors include Wasatch Advisors LP (1.49%), Assenagon Asset Management S.A. (0.92%), WCM Investment Management LLC (0.46%), BNP Paribas Financial Markets (0.19%), GSA Capital Partners LLP (0.07%) and Diversified Trust Co (0.07%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Karen Prange, Karl S Dahlquist, Maggie Yuen, Mark A Collar, Mark A Collar, Regina E Groves, Salvatore Privitera, Scott William Drake, Tonya Austin and Vinayak Doraiswamy. View institutional ownership trends. How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does AtriCure have any subsidiaries? The following companies are subsidiares of AtriCure: SentreHEART.Read More This page (NASDAQ:ATRC) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe only AI company you should be looking atBehind the MarketsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.